CN102427828A - 含具有信号肽的细菌毒素作为载体的半抗原-载体缀合物和它们在免疫原性组合物中的用途 - Google Patents

含具有信号肽的细菌毒素作为载体的半抗原-载体缀合物和它们在免疫原性组合物中的用途 Download PDF

Info

Publication number
CN102427828A
CN102427828A CN2010800175877A CN201080017587A CN102427828A CN 102427828 A CN102427828 A CN 102427828A CN 2010800175877 A CN2010800175877 A CN 2010800175877A CN 201080017587 A CN201080017587 A CN 201080017587A CN 102427828 A CN102427828 A CN 102427828A
Authority
CN
China
Prior art keywords
immunogenic composition
nicotine
signal peptide
ctb
hapten
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800175877A
Other languages
English (en)
Chinese (zh)
Inventor
威廉·亨利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102427828A publication Critical patent/CN102427828A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800175877A 2009-03-09 2010-03-09 含具有信号肽的细菌毒素作为载体的半抗原-载体缀合物和它们在免疫原性组合物中的用途 Pending CN102427828A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20962909P 2009-03-09 2009-03-09
US61/209,629 2009-03-09
PCT/EP2010/052997 WO2010103017A2 (en) 2009-03-09 2010-03-09 Hapten-carrier conjugates with bacterial toxins having a signal peptide as carrier and their use in immunogenic compositions

Publications (1)

Publication Number Publication Date
CN102427828A true CN102427828A (zh) 2012-04-25

Family

ID=42555592

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800175877A Pending CN102427828A (zh) 2009-03-09 2010-03-09 含具有信号肽的细菌毒素作为载体的半抗原-载体缀合物和它们在免疫原性组合物中的用途

Country Status (9)

Country Link
US (1) US20120100171A1 (enExample)
EP (1) EP2405943A2 (enExample)
JP (1) JP2012519724A (enExample)
KR (1) KR20120022760A (enExample)
CN (1) CN102427828A (enExample)
CA (1) CA2754592A1 (enExample)
MX (1) MX2011009359A (enExample)
RU (1) RU2011140858A (enExample)
WO (1) WO2010103017A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113825984A (zh) * 2019-05-20 2021-12-21 美国西门子医学诊断股份有限公司 用于检测免疫测定中由多半抗原试剂的不完全递送引起的异常结果的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730328C (en) * 2008-09-03 2015-03-31 Board Of Trustees Of Michigan State University Immunogenic escherichia coli heat stable enterotoxin
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
WO2011041483A2 (en) * 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
US10160789B2 (en) 2011-03-14 2018-12-25 University Of Louisville Research Foundation, Inc. Polypeptides having immunoactivating activity and methods of producing the same
US10758605B2 (en) 2015-06-29 2020-09-01 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US20210277071A1 (en) * 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
EP3993836A1 (en) * 2019-07-03 2022-05-11 Intervet International B.V. Conjugated deoxynivalenol to protect against mycotoxicosis
US12343375B2 (en) 2021-02-09 2025-07-01 University Of Louisville Research Foundation, Inc. Spray dried formulation of a cholera toxin B subunit variant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1513995A (zh) * 2003-04-15 2004-07-21 中国科学院微生物研究所 一种多形汉逊酵母表达重组霍乱毒素b亚单位基因及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4883761A (en) 1986-03-25 1989-11-28 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
JP2661044B2 (ja) 1986-06-17 1997-10-08 カイロン コーポレイション 肝炎δの診断薬およびワクチン
HU216017B (hu) 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
JP2656995B2 (ja) 1989-03-17 1997-09-24 カイロン コーポレイション Ｎａｎｂｖの診断用薬
MC2188A1 (fr) 1989-05-18 1992-09-16 Chiron Corp Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
US5773003A (en) 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US5876727A (en) 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US20020032316A1 (en) 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
FR2768747B1 (fr) 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
GB0325494D0 (en) 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1513995A (zh) * 2003-04-15 2004-07-21 中国科学院微生物研究所 一种多形汉逊酵母表达重组霍乱毒素b亚单位基因及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARIANNE JERTBORN 等: "Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers", 《VACCINE》 *
THOMAS R. KOSTEN 等: "Human therapeutic cocaine vaccine: safety and immunogenicity", 《VACCINE》 *
XENOVA研究组: "Anti-Smoking Vaccine TA-NIC Preliminary 12 Month Clinical Trial Results", 《NEWS RELEASE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113825984A (zh) * 2019-05-20 2021-12-21 美国西门子医学诊断股份有限公司 用于检测免疫测定中由多半抗原试剂的不完全递送引起的异常结果的方法

Also Published As

Publication number Publication date
CA2754592A1 (en) 2010-09-16
KR20120022760A (ko) 2012-03-12
JP2012519724A (ja) 2012-08-30
US20120100171A1 (en) 2012-04-26
RU2011140858A (ru) 2013-04-20
WO2010103017A2 (en) 2010-09-16
MX2011009359A (es) 2011-12-16
EP2405943A2 (en) 2012-01-18
WO2010103017A3 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
CN102427828A (zh) 含具有信号肽的细菌毒素作为载体的半抗原-载体缀合物和它们在免疫原性组合物中的用途
EP1024834B1 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
EP1329226B1 (en) Hapten-Carrier Conjugates for use in Drug Abuse Therapy
WO1998014216A9 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US11739054B2 (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
WO2007097251A1 (ja) 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン
ES2287379T3 (es) Conjugados de hapteno-transportador para usar en terapia del abuso de drogas.
US20060002960A1 (en) GM1 binding deficient exotoxins for use as immunoadjuvants
CA2912496A1 (en) Immunogenic composition for use in therapy
US20060058220A1 (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
Romano et al. A two-dose regimen of Qβ virus-like particle-based vaccines elicit protective antibodies against heroin and fentanyl
KR102743672B1 (ko) 점막에서 항원 특이적 면역 반응을 증진시키는 신규한 펩타이드 및 상기 펩타이드를 유효성분으로 포함하는 점막 백신 보조제
KR100538388B1 (ko) 약물남용 치료시에 사용되는 불완전항원-담체 포합체 및 상기 포합체의 제조방법
AU772309B2 (en) Hapten-carrier conjugates for use in drug-abuse therapy
HK1027293B (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
TW200810773A (en) Use of tight junction agonists to facilitate the pulmonary delivery of therapeutic agents
HK1110794A (en) Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
WO2013154744A1 (en) Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
HK1103035A (en) Hapten-carrier conjugates for use in drug-abuse therapy (cocaine)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120425